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ABSTRACT 
 
The objective of this study was to design and developed a rupturable coating type of pulsatile press coated tablet, which 
releases drug early in the morning hours. This delivery system was helpful to control an early morning surge in Blood Pressure because 
cardiovascular events occur more frequently in the morning. This delivery system would be useful for the prevention of cardiovascular 
events in hypertensive patients. Initially core tablet was prepared by using Nimodipine as a drug, and different concentration of cross 
carmellose sodium, Poly vinyl pyrrolidone k30 as a superdisintegrant by the direct compression method. Core tablet was press coated 
by using Eudragit S-100 ratios as a press coating polymers. In-vitro drug release was found to be 98 % from coated tablets in 15 min 
after 7 hrs lag time. FT-IR spectra revealed that there is no chemical incompatibility between the drug and other excipients. Scanning 
electron micrograph of optimized tablet shown that the thickness level in the coating. The results concluded the programmable 
pulsatile release has been achieved from coated tablets after a lag time of 5 hrs, which is consistent with the demands of the 
chronotherapeutic drug delivery and increasing bioavailability. 
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INTRODUCTION 
 
Oral route of drug delivery is typically considered the 
favored and the most preferable having the highest degree of 
patient compliance. There are many conditions and diseases 
where sustained release formulations do not show good 
efficiency such conditions demand the release of drug after a lag 
time i. e form of pulse. If the timing of dosage regimen is 
adjusted according to cyclic rhythm of diseases effective 
management can be achieved [1, 2]. The rationale of the present 
study is to develop a drug delivery system which provides 
required dose at the required time without any failure. Pulsatile 
drug delivery system solves this problem, a single capsule 
ingested at the bedtime releases drug early in the morning 
which gives protection from cardiovascular events. High blood 
pressure or hypertension as a disease is known medically most 
common chronic illness [3-6]. 
 
Pulsatile systems are designed in a manner that the 
drug is available at the site of action at the right time in the right 
amount [7]. The concept of chronotherapeutics originates from 
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the finding of the major disease conditions such as asthma, 
cardiac disorders, allergic rhinitis, and arthritis following 
circadian example of symptom outburst. Nimodipine is 
a calcium channel blocker originally developed for the 
treatment of high blood pressure. It is not frequently used for 
this indication, but has shown good results in preventing a 
major complication of subarachnoid hemorrhage (a form of 
cerebral hemorrhage) termed vasospasm; this is now the main 
use of Nimodipine. 
 
MATERIALS AND METHODS 
 
Materials: Nimodipine was chosen as a model drug and 
obtained from Chandra labs as a gift sample. Poly vinyl 
pyrrolidone k30, Croscarmellose Sodium, Microcrystalline 
cellulose used as super disintegrants , magnesium stearate, talc 
obtained from Vijlak Pharma Limited, and obtained from Hetero 
Drugs , Eudragit S 100, used as PH sensitive polymers and 
obtained from Chandra labs. 
 
Pre-Formulation Studies: 
Compatibility studies: 
Compatibility of drug Nimodipine with excipients was 
established by IR absorption spectral analysis. Its spectral 
analysis of pure Nimodipine, pure excipients and combination 
of the drug with excipients carried out to investigate any change 
in chemical composition of the drug after combining with 
excipients. 
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Method: 
The spectrum analysis of pure drug and physical 
mixture of drug and different excipients which are used for 
preparation of granules were studied by FTIR. FTIR spectra 
were recorded by preparing potassium bromide (KBr) disks 
using a shimadzu corporation (japan) facility (model-8400S). 
Potassium bromide (KBr) disks were prepared by mixing few 
mg of sample with potassium bromide by compacting in a 
hydrostatic press under vacuum at 6-8 tons pressure. The 
resultant disc was mounted in a suitable holder in IR 
spectrophotometer and the IR spectrum was recorded from 
4000cm
-1 
to 500cm
-1 
in a scan time of 12 minutes.  The 
resultant spectrum was compared for any spectral for any 
spectral changes. They were observed for the presence of 
characteristics peaks for the respective functional group in the 
compound. 
 
Spectroscopic studies: 
Preparation of standard stock solution:  
Standard drug solution of Nimodipine was prepared 
by dissolving 10 mg of Nimodipine in 10ml of pH 6.8 Phosphate 
buffer containing 0.05 % w/v of SLS in volumetric flask to give 
stock solution of 1000 μg/ml. 1ml of stock solution was 
withdrawn and further diluted with pH 6.8 Phosphate buffer 
containing 0.05 % w/v of SLS solution to give stock solution of 
100 μg/ml concentration.  
 
Preparation of calibration curve: 
Calibration curve was prepared in pH 6.8 Phosphate 
buffer containing 0.05 % w/v of SLS solution at λmax of 238.5 
nm by using Jasko UV-Visible spectrophotometer. For this stock 
solution of 100μg/ml was prepared. Serial dilutions of 5, 10, 15, 
20, 25 and 30 μg/ml were prepared and absorbance was taken 
at 238.5 nm. The solutions were scanned in the range of 200-
400 nm against blank. The calibration curve was plotted.  
 
Formulation development: 
1.   Preparation of Nimodipine core tablet by direct compression 
method. 
2.   Coating for core tablet. 
 
Preparation of Nimodipine core tablet by direct compression 
method: 
All the ingredients (Nimodipine, Poly vinyl pyrrolidone 
k30, Croscarmellose Sodium, Microcrystalline cellulose) were 
triturated individually in a mortar and passed through 
#60sieve. Then required  of  all  ingredients  were  weighted  for  
a  batch  size of  50  tablets  and  mixed Uniformly in a mortar 
except talc and magnesium stearate. Finally magnesium 
stearate and talc were added as lubricant and glident.  This 
uniformly mixed blend was compressed in to tablets 
containing 30 mg drug using 5mm flat face surface punches on 
a cemach rotary tablet machine by direct compression 
method total weight of tablet was kept 100mg. 
 
Three different weights 6.5gms, 12.5gms and 24.5grms 
of Eudragit L-100 was weighed and transferred into 100mL 
beaker to it    50mL  of  acetone  was  added  and  it  was  
thoroughly  mixed  for  10min  then  add remaining amount 
50mL of acetone to it then it forms 12.5%(w/v) of Eudragit 
S100 coating solution. This coating will be dissolved in acidic pH 
and releases the drug at pH 6-7. 
 
It was done by using the standard coating pan, where 
fixed numbers of tablets were coated each time by atomizing the 
polymeric coating solution through the means of spray gun. The 
scale-up variables including pan loading, pan speed, number of 
spray guns, spray rate, and inlet airflow etc. were considered. 
About 50 tablets of Nimodipine tablet were taken and allow to 
coatings in pan coater at 30 rpm and 50oC temperature. Coating 
was carried out with praying method and dried with same. 
Table No. 1: Formulation of Pulsatile Release Tablet of Nimodipine 
INGREDIENTS 
(mg) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 
Nimodipine 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 
Croscarmellose 
sodium 
2 4 6 8 10 12 - - - - - - - - - - - - 
Poly vinyl 
pyrrolidone k30 
- - - - - - 1 2 4 5 6 7 - - - - - - 
Sodium starch 
glycolate 
- - - - - - - - - - - - 2 4 6 8 10 12 
Micro crystalline 
cellulose 
84 82 80 78 76 74 85 84 82 81 80 79 84 82 80 78 76 74 
Magnesium 
Stearate 
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Total weight 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 
 
Coating Solution: 
Table No. 2: Coating solution (Trail 1) 
 
S.NO INGREDIENTS QUENTITY 
1 Eudragit S-100 3.5g 
2 Acetone 100Ml 
 
Table No. 3: Coating solution (Trail 2) 
 
S.NO INGREDIENTS QUENTITY 
1 Eudragit S-100 12.5g 
2 Acetone 100Ml 
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Table No. 4: Coating solution (Trail 3) 
 
S.NO INGREDIENTS QUENTITY 
1 Eudragit S-100 24.5g 
2 Acetone 100Ml 
 
Evaluation for formulation: 
Pre formulations like Bulk density, Tapped density, Angle of 
repose were studied and post formulation: Weight variation, 
Thickness, Hardness, Friability, Content uniformity, In-vitro 
Disintegration time, In-vitro dissolution studies, Accelerated 
stability studies were studied. 
 
In-vitro Disintegration time: 
The USP device to rest disintegration was six glass 
tubes that are”3 long, open at the top, and held against 10” 
screen at the bottom end of the basket rack assembly. One tablet 
is placed in each tube and the basket rack is poisoned in one 
liter beaker of buffer at 37 ± 20C, such that the tablets 
remain below the surface of the liquid on their upward 
Movement and descend not closer than 2.5 cm from the bottom 
of the beaker. 
 
In-vitro release studies: 
In-vitro drug release of PDDS capsule was determined 
using USP dissolution apparatus II (paddle type) (electro lab 
TDT-08L). The dissolution studies were carried out in 0.1N HCl 
for 2 hrs, then 4 hrs in pH 6.8 phosphate buffers and finally 1hr 
in pH 7.4 phosphate buffer at every specific interval 5mL 
sample were withdrawn and it was replaced by fresh 
medium with respect to medium at the time to maintain the 
volume constant. After appropriate dilution, the sample solution 
was analyzed at 255 nm for Nimodipine by a UV-
spectrophotometer. The amount of drug present in the sample 
was calculated with the appropriated calibration curve. Also the 
study was carried out in triplicates. 
 
Dissolution apparatus: USP dissolution apparatus II 
(paddle type) (electrolab TDT- 08L). 
 
Dissolution media: 0.1 N HCl for 2 hrs, pH 6.8 phosphate buffer 
for 4 hr, pH 6.8 phosphate buffer for 1 hr. 
 
Volume of dissolution media: 900mL. 
 
Aliquot withdrawn: 5mL. 
 
Revolutions for minute (speed): 50. 
 
Bath temperature: 37±0.50C. 
 
Kinetic Data /Model Fitting of Drug Release from 
Formulated Matrix Tablets: 
Drug release mechanisms and kinetics are two 
characteristics of the dosage forms which play an important role 
in describing the drug dissolution profile from a controlled 
release dosage forms and hence there in vivo performance.  The 
diffusion data obtained is fitted to mathematical models and the 
best fit is obtained to describe the release mechanism of the 
drug. 
 
A number of mathematical models have been 
developed to describe the drug dissolution kinetics from 
controlled release drug delivery system as follow as,  
 
 Higuchi (cumulative % drug release versus square root of 
time);  
 First order (log cumulative % drug remaining versus time),  
 Zero order (cumulative % drug release versus time) and  
 Peppas and Korsemeyer model (log cumulative % drug 
release versus log time).   
 
Accelerated stability studies: 
Stability of drug has defined by Lachman L (1987) 
the ability of particular formulation, in   specific   container,   to   
remain   within   its   physical,   chemical,   therapeutic   and 
toxicological specifications. The purpose of stability testing 
is to provide evidence on how the quality of a drug substance 
or drug products varies with time under the influence of a 
variety of environmental factors such as temperature, humidity 
and light, and enables recommended storage conditions, re-
tested and self-life to be established. 
 
ICH specific the length of study and storage conditions: 
Accelerated testing 400C ± 20C / 75% RH ± 5% for 30 days.  
 
Procedure: 
In the present study, stability was carried out at 400C ± 
20C / 75% RH for a specific time up to 30 days for selected 
formulation. 
 
RESULTS AND DISCUSSION 
 
Pre-Formulation Studies: 
Compatibility study: 
IR interpretation of Nimodipine PR tablet: Spectrum of 
prepared Nimodipine pulsatile release tablets were compared 
the pure drug IR spectra, showed no significant change in the 
appearance of characteristics peaks of pure drugs spectra. This 
indicates that the drug is compatible with formulation 
components. The spectra are shown below 
 
 
Table No. 5: Determination of FTIR Functional groups of Nimodipine 
 
S. No Functional Groups Reference Peaks (Cm -1) Observed Peaks (Cm -1) 
1 N-H 10
 
stretching vibration 2312-3389 2387 
2 N-H 10
 
stretching vibration 2143-2150 2148 
3 C=N stretching 1725-1739 1730 
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Fig. 1: FTIR spectrum of pure drug 
 
 
 
Fig. 2: FTIR spectrum of pure drug + Poly vinyl pyrrolidone k30 
 
 
 
Fig. 3: FTIR spectrum of pure drug + Croscarmellose Sodium 
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DSC: 
 
 
 
Fig. 4: DSC of Nimodipine Pure drug 
 
The thermal behavior of Nimodipine was studied using DSC Thermogram. The DSC Thermogram of Nimodipine exhibited an 
endothermic peak at 125.5 oC. 
 
 
 
Fig. 5: DSC of Nimodipine + Excipient mixture 
 
The thermal behavior of drug and physical mixture of 
drug and polymer was studied by using DSC Thermogram. DSC 
thermogram of drug exhibited characteristic peak at 125.5oC. 
 
Analytical method development: 
Determination of λmax of drug solution: 
λmax o f   Nimodipine  was  determined  using  UV  
spectrophotometer against pH 6.8 phosphate buffer as blank. 
Maximum absorbance was observed at 238.5 nm (λmax) of 
prepared sample. This was considered as λmax of solution and 
absence of any impurity must be ensured. 
 
Preparation of standard stock solution of Nimodipine drug: 
Working standard stock solution of Nimodipine was 
prepared as discussed in Methodology. From working standard 
stock solution of the drug, working standard stock solution was 
prepared from which working dilutions of  5, 10, 15, 20, 25, 30 
µ g/mL were prepared and analyzed for absorbencies at 238.5  
nm against pH 6.8 phosphate buffer as blank. 
 
Standard calibration curve of Nimodipine: 
Linearity of prepared solution was found in the range 
of 5 to 30µg/mL. From regression analysis value of co-efficient 
of regression (R2) was 0.9998. This confers the range selection 
was satisfactory and follows Beer-Lambert’s law. 
 
Kinetic Analysis of Dissolution Data: 
The release rate kinetic data of optimized formulation 
PR8 of matrix tablets are shown in Table 7. 
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Fig. 6:  Standard graph of Nimodipine 6.8 phosphate buffer 
 
Table No. 6: Bulk density, Tapped density, Carr’s index, Hausner ratio, Angle of repose, %drug content 
 
Formulation 
Code 
Bulk 
density 
(mg/ml) 
Tapped 
density 
(mg/ml) 
Angle 
of repose 
Carr’s 
index 
Hausners 
ratio 
%Drug 
content 
F1 0.66±0.05 0.67±0.08 24.34±0.44 09.23±1.12 1.13±0.24 97.23±1.23 
F2 0.51±0.07 0.68±0.06 22.67±0.31 08.23±1.42 1.11±0.10 98.04±1.03 
F3 0.55±0.06 0.64±0.00 26.54±0.41 10.12±0.8 1.13±0.20 96.56±0.94 
F4 0.56±0.09 0.66±0.08 25.89±0.55 11.34±0.6 1.14±0.24 98.11±0.63 
F5 0.52±0.03 0.66±0.07 22.56±0.0.57 12.23±0.12 1.11±0.32 95.23±0.81 
F6 0.51±0.08 0.63±0.06 25.30±0.30 11.23±0.25 1.12±0.30 96.45±0.32 
F7 0.52±0.03 0.61±0.05 22.56±0.57 10.34±0.31 1.14±0.20 95.11±1.17 
F8 0.58±0.03 0.68±0.09 23.67±0.60 09.11±0.24 1.12±0.25 98.23±0.45 
F9 0.56±0.06 0.67±0.03 25.56±0.44 09.45±1.15 1.13±0.70 97.13±1.17 
F10 0.66±0.05 0.52±0.05 21.06±0.31 13.45±1.3 1.09±0.20 96.23±0.49 
F11 0.54±0.09 0.58±0.07 22.34±0.37 14.23±1.5 1.13±0.16 98.97±0.95 
F12 0.57±0.06 0.64±0.01 25.99±0.70 11.34±1.25 1.12±0.12 98.45±0.35 
F13 0.57±0.07 0.68±0.05 23.14±0.50 09.67±1.55 1.09±0.14 99.85±0.24 
F14 0.59±0.05 0.59±0.08 22.09±0.57 10.23±1.55 1.14±0.15 99.18±0.13 
F15 0.57±0.08 0.66±0.04 24.78±0.77 10.45±1.5 1.15±0.15 99.25±1.21 
F16 0.58±0.00 0.64±0.06 23.45±0.80 09.681.3 1.18±0.18 97.45±1.30 
F17 0.51±0.04 0.68±0.07 21.89±0.86 09.47±1.09 1.12±0.15 99.94±1.31 
F18 0.54±0.06 0.61±0.09 23.05±0.75 14.99±1.20 1.14±0.15 98.56±1.36 
Above parameters are communicated as Average ± Standard Deviation; (n=3) 
 
In vitro dissolution study: 
 
 
 
Fig. 7:  in vitro Drug Release Profile for immediate release tablet of Nimodipine F1-F6 
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Fig. 8: in vitro Drug Release Profile for immediate release tablet of Nimodipine F7-F12 
 
 
 
Fig. 9: in vitro Drug Release Profile for immediate release tablet of Nimodipine F13-F18 
 
 
 
Fig. 10: in vitro Drug Release Profile for Trail 1 Prepared middle active layer of Nimodipine tablets F4, F10, F18 
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Fig. 11: in vitro Drug Release Profile for Trail 2 Prepared middle active layer of Nimodipine tablets F4, F10, F18 
 
 
 
Fig. 12: in vitro Drug Release Profile for Trail 3 Prepared middle active layer of Nimodipine tablets F4, F10, F18 
 
Table No. 7: Comparison of Kinetic Data of Optimized Formulation F10 
 
Formulation 
Code 
Zero Order First Order Higuchi Korsmeyer-Peppas 
R2 n R2 n R2 n R2 N 
F4 0.919 8.689 0.994 0.140 0.937 29.01 0.709 2.475 
 
Table No. 8: Stability studies 
 
Parameters Time (Months) 
0 Initial 1st month 2nd month 3rd month 
Strength No Change No Change No Change No Change 
Color No Change No Change No Change No Change 
Drug Content (%) 98.23 ± 1.40 99.23 ± 2.98 98.23 ± 1.48 97.94 ± 2.54 
In-vitro drug release 99.24 99.54 99.23 99.42 
 
DISCUSSION 
 
The immediate release tablets were prepared by using 
different types and   different concentration of 
superdisintegrating agents like Croscarmellose, Poly vinyl 
pyrrolidone k30 and sodium starch glycolate. For immediate 
release tablets dissolution studies were performed in that three 
best formulations were selected (F4, F10, F18) for pulsatile 
release formulation. Selected three formulations were coated 
with three trails were of different weights of coating material 
used for trail 1 6.5gm of coating material was used, trail 2 
12.5gm of coating material was used and trial 3 24.5gm of 
coating material was used. Trial 2 was showed good release 
pattern. The polymer Poly vinyl pyrrolidone k30 shows good 
drug release profile than Croscarmellose and sodium starch 
glycolate. The 5% Poly vinyl pyrrolidone k30 shows better 
results. Formulations prepared by using Croscarmellose 8 % 
showed the maximum amount of drug release 84.24%after 7th 
hour in pulsatile release formulations. Formulations prepared 
by using Poly vinyl pyrrolidone k30 5% showed the maximum 
amount of drug release 98.42% after 7th hour in pulsatile 
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release formulations. The coating polymer Eudragit S-100(50% 
weight gain) produces the lag time of 6hrs. From the above drug 
release profile the F10 was selected as best formulation. The 
corresponding plot (Log Cumulative Drug Release Vs Log time) 
for Korsmeyer – Peppas equation indicated a good linearity 
(r2=0.709). The diffusional exponent “n” was 2.475, which 
appears to indicating the release of drug polymer matrix 
formulations was found to be super case-II transport, i.e., drug 
release by more than one mechanism. Super case II transport 
generally refers to erosion of polymeric chain and anomalous 
transport. Drug- excipient interactions play a crucial role with 
respect to the stability and potency of the drug. FT-IR 
techniques have been used to study the physical and chemical 
interaction between drug and excipients used. There was no 
significance difference between the absorption peaks of pure 
drug and optimized formulation. The results concluded that 
there was no interaction between pure drug and excipients. The 
stability of this optimized formulation was known by 
performing stability studies for three months at accelerated 
conditions of 400C + 75 % RH on optimized formulation. The 
formulation was found to be stable, with no change in the 
weight variation, thickness, and friability, hardness, drug 
content and In vitro drug release pattern. 
 
CONCLUSION 
 
 A chronotherapy based pulsatile release tablets of 
Nimodipine was successfully developed, Taking into 
consideration the chronotherapy of hypertension, pulsatile 
release tablet with 120mg tablet. Formulation F10 gave 
satisfactory release lag time of 7 drug release within 15min. 
Hence this formulation can be helpful for the patients with 
morning surge. 
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